









Bioequivalence, Dissolution, Biosimilarity

From the "Chain Bridge" to other Bridges of the Pharmaceutical World

25 April 2015

Akra Barut Hotel, Antalya, Türkiye

PROGRAMME

09:00-10:00	Registration
10:00-10:15	Opening Nevin Çelebi, TÜFTAD President, Gazi University Turkey Atilla Hıncal, İDE Pharmaceutical Consultancy Ltd Co, Turkey Laszlo Endrenyi, University of Toronto, Canada Vinod Shah, VPS Consulting, LLC, USA
10:15-10:35	Story of the Hungarian bioequivalence workshop series Imre Klebovich, Semmelweis University, Hungary
10:35-10:55	The legal basis for applications: an issue of understated importance in the EU <i>Tamás Paál</i> , University of Szeged, Hungary
10:55-11:15	Points to consider during the development of a generic modified-release dosage form Vinod Shah, VPS Consulting, LLC, USA
11:15-11:35	Requirements of various regulatory authorities for the bioequivalence of modified-release drug products Laszlo Endrenyi, University of Toronto, Canada
11:35-11:55	Coffee break
11:55-12:15	In vitro-in vivo correlations: an update José Morais, Unversidade de Lisboa, Portugal
12:15-12:35	In vitro-in vivo correlations: traditional approach Nikoletta Fotaki, University of Bath, UK
12:35-14:00	Lunch
14:00-14:20	Formulation of drug-loaded microfiber based solid dosage forms for in vitro dissolution enhancement of poorly soluble drugs Romána Zelkó, Semmelweis University, Hungary

PROGRAMME 14:20-14:40 Biowaiver applications in the European scenario Carla Caramella, University of Pavia, Italy Tyrosine kinase inhibitors (TKIs) -Challenges for 14:40-15:00 anticancer therapy and regulatory perspectives Milena Jadrijevic-Mladar Takac, University of Zagreb, Croatia 15:00-15:20 The place of capillary electrophoresis among bioanalytical separation techniques (Joint presentation with Tamás Tabi) Éva Szökő, Semmelweis University, Hungary 15:20-15:40 Tea break 15:40-16:00 **Emerging technologies: Milk based formulations** Panos Macheras, University of Athens, Greece Biosimilars: The challenge of making an informed 16:00-16:20 decision in therapy Clive Wilson, Strathclyde Institute of Pharmacy & **Biomedical Sciences, UK** 16:20-16:40 Developing biosimilars biobetters & development in Turkey Atilla Hincal, IDE Pharmaceutical Consultancy Ltd Co, Turkey Similars of nonbiological complex drugs (NBCDs): 16:40-17:00 challenges for a regulatory approach Stefan Mühlebach, Vifor Pharma, Glattbrugg, **Switzerland** 17:00-17:20 Uncertainties in the analysis of clinical trials Constantin Mircioiu, Carol Davila University, Romania 17:20 **Closing** Atilla Hıncal, TÜFTAD Honorary President, İDE **Pharmaceutical Consultancy Ltd Co, Turkey**

Formu doldurduktan sonra kayıt ücretinin ödendiğine dair dekont ile birlikte aşağıdaki iletişim adresine gönderiniz. Son Kayıt Tarihi: 20 Nisan 2015 Prof.Dr. Füsun Acartürk Gazi Üniversitesi Eczacıllık Fakültesi 06330 Hipodrom - Ankara E-posta: fusun.acarturk@gmail.com • Tel:+90.312.202 30 50 Ad - Soyad: Ünvan: Firma : Adres : Telefon : Faks : E-posta :

Kayıt Ücreti: 300 TL

TÜRK FARMASÖTİK TEKNOLOJİ ARAŞTIRMACILARI DERNEĞİ

Yapı Kredi Bankası Hacettepe Şubesi (Şube Kodu: 0483) • Hesap No: 71090937 • IBAN: TR31 0006 7010 0000 0071 0909 37